**
In a troubling revelation, internal documents indicate that senior officials from the Trump administration engaged in discussions with Bayer’s CEO, Bill Anderson, about the ongoing legal battles surrounding the company’s glyphosate-based herbicides. This meeting, held on 17 June, took place just months before the administration took significant steps that appeared to bolster Bayer’s position in the courts. Critics are now questioning the integrity of regulatory processes and the extent of corporate influence over public health policies.
Meeting with a Purpose
The records obtained by the Centre for Biological Diversity reveal that the Environmental Protection Agency (EPA) hosted a significant meeting with Bayer executives, including Anderson, as they sought to address the mounting litigation against the company. Thousands of plaintiffs allege that exposure to glyphosate products, such as Roundup, has caused serious health issues, including cancer. Central to these lawsuits is the accusation that Bayer neglected to inform users about the cancer risks associated with its products.
Bayer has indicated that one of its strategies to mitigate the financial impact of these lawsuits—costing the company billions—lies in persuading the Supreme Court that if the EPA does not mandate a cancer warning, the company should not be held liable for failing to issue one.
Regulatory Complicity?
The timing of the meeting raises eyebrows. Less than two weeks later, the Supreme Court sought input from the Justice Department regarding Bayer’s case, indicating a potential alignment of interests between the Trump administration and the pharmaceutical giant. The EPA officials present included Lee Zeldin, the agency’s administrator, and Nancy Beck, who previously held a prominent role at the American Chemistry Council.
Environmental advocates are alarmed by what they perceive as an alarming trend of regulatory agencies prioritising corporate interests over public health. Nathan Donley, director of environmental health science at the Centre for Biological Diversity, emphasised that the meeting underscores the troubling power dynamics at play. “When the CEO of one of the largest companies in the world is meeting with political appointees in a US regulatory office, it shows just how much power and influence these corporations have,” he stated.
Patterns of Support
Since the June meeting, the Trump administration has actively supported Bayer’s legal battles. In a filing dated 1 December, Solicitor General D John Sauer—appointed by the administration—urged the Supreme Court to hear Bayer’s case, which the court subsequently agreed to, scheduling a hearing for 27 April. Additionally, on 18 February, the White House invoked the Defense Production Act to safeguard glyphosate production, further solidifying Bayer’s position in the market.
Legal experts have raised concerns about the implications of such close ties between corporate entities and government officials. Whitney Di Bona, an attorney and consumer safety advocate, expressed her unease, noting, “It’s concerning that the CEO of a major pesticide company can have private meetings with the EPA to talk about limiting the company’s liability.”
Corporate Access versus Public Voices
The disparity in access to regulatory agencies is striking. Naomi Oreskes, a professor at Harvard, commented on the systemic issue, highlighting a pattern of industry leaders receiving preferential treatment from government officials. In stark contrast, those affected by glyphosate exposure, including cancer survivors and their families, have found their voices largely sidelined in these discussions.
Zen Honeycutt, founder of Moms Across America, echoed these sentiments, describing the ongoing influence of chemical companies over regulatory agencies as a longstanding issue. Despite repeated efforts by advocacy groups to engage with the EPA, tangible outcomes remain elusive. “Coercion by chemical companies on our regulatory agencies is nothing new,” she said.
Why it Matters
This emerging narrative of corporate influence raises critical questions about the integrity of public health regulations and the protection of citizens from potentially harmful products. As Bayer continues its battle to limit liability and bolster profits, the ramifications of these high-level meetings could reverberate across the landscape of environmental policy and consumer safety. With the stakes higher than ever, it is vital for the public to remain vigilant and demand transparency and accountability in the actions of both corporations and government officials. The health and safety of millions depend on it.
